论文部分内容阅读
目的:探讨吸入性皮质激素(ICS)与白三烯受体拮抗剂(LTRAs)联合应用对变应性鼻炎(AR)的影响。方法:将对ICS无反应的47例患者用LTRAs孟鲁斯特治疗2周,其中单独应用孟鲁斯特26例(B组),与糠酸莫米松合用21例(C组),用生理盐水滴鼻和口服维生素C的10例AR患者为对照组(A组),治疗前后对患者症状进行评分,对各组间症状进行评分。结果:在AR患者中有少部分患者对激素不敏感;且出现的比例在并发有哮喘症状的AR患者中较其他无并发症状的患者要高,差异有统计学意义(P<0.05);与A组患者相比,B组患者症状有明显改善,差异有统计学意义(P<0.05);C组患者的症状控制更为有效,差异有统计学意义(P<0.05)。结论:对ICS不敏感的AR患者可以选择LTRAs辅助治疗;并可同时用ICS和LTRAs控制AR的症状。
Objective: To investigate the effects of inhaled corticosteroids (ICS) combined with leukotriene receptor antagonists (LTRAs) on allergic rhinitis (AR). METHODS: Forty-seven patients who did not respond to ICS were treated with montelukast LTRAs for 2 weeks, including 26 montelukast (group B) alone and 21 (group C) mometasone furoate combined with physiologic Ten AR patients undergoing saline drip and oral administration of vitamin C were given as control group (group A). The symptoms of patients were scored before and after treatment, and the symptoms among the groups were scored. Results: A small proportion of patients with AR were not sensitive to hormones. The proportion of patients with AR was higher than those without complications in AR patients complicated with asthma (P <0.05) Compared with patients in group A, the symptoms in group B were significantly improved (P <0.05). The symptoms in group C were more effective and the difference was statistically significant (P <0.05). CONCLUSIONS: LTRAs adjuvant therapy is available for patients with ICS who are not susceptible to ICS. ARS may be controlled by both ICS and LTRAs.